Previous Article | Next Article 
Journal of Virology, June 2001, p. 5084-5089, Vol. 75, No. 11
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5084-5089.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Efficient Infection of Primary Tupaia Hepatocytes
with Purified Human and Woolly Monkey Hepatitis B Virus
Josef
Köck,
Michael
Nassal,
Sabine
MacNelly,
Thomas F.
Baumert,
Hubert E.
Blum, and
Fritz
von Weizsäcker*
Department of Medicine II, University of
Freiburg, Freiburg, Germany
Received 17 November 2000/Accepted 6 March 2001
 |
ABSTRACT |
The Asian tree shrew, Tupaia belangeri, has been
proposed as a novel animal model for studying hepatitis B virus (HBV)
infection. Here, we describe a protocol for efficient and reproducible
infection of primary tupaia hepatocytes with HBV. We report that human
serum interferes with HBV binding to the hepatocytes, thus limiting the
maximum multiplicity of infection. Purification of HBV virions by
gradient sedimentation greatly enhances virus binding and infectivity. Covalently closed circular DNA was clearly detectable by Southern blot
analysis and newly synthesized single-stranded HBV DNA was visible 2 weeks postinoculation. Primary tupaia hepatocytes are also susceptible
to infection with the recently discovered woolly monkey hepatitis B
virus (WMHBV) but not to woodchuck hepatitis virus infection. Compared
to HBV, WMHBV replicated at a higher rate with single-stranded DNA
detectable within the first week postinoculation. Primary tupaia
hepatocytes should represent a useful system for studying early steps
of HBV and WMHBV infection.
 |
INTRODUCTION |
With an estimated 350 million
chronically infected people worldwide, hepatitis B virus (HBV)
infection represents a major health care problem. Every year nearly 1 million individuals succumb to HBV-associated liver diseases, such as
cirrhosis and hepatocellular carcinoma (9, 18). Although
an efficient and safe vaccine is available, HBV is spreading,
especially in Asia and Africa (10). Treatment of chronic
HBV infection is still unsatisfactory. At present, alpha interferon and
lamivudine are the only therapeutic options available in clinical
practice. However, alpha interferon yields a sustained suppression of
viral replication in only about one-third of patients, and lamivudine
resistance with mutations in the viral polymerase gene is a frequent
event in lamivudine-treated patients (3, 7). Based on
transfection studies of hepatoma cell lines, the mechanisms of HBV
replication have been elucidated in great detail (11, 13).
By contrast, little is known about the early events of the viral life
cycle. Unfortunately, permanent cell lines are not permissive to HBV
infection, and primary human hepatocytes are not easily available for
in vitro infection studies. Furthermore, the quality of liver tissue
obtained at surgery for the preparation of primary human hepatocytes is
highly variable (5). Therefore, alternative experimental
systems for studying HBV infection are urgently needed.
Two reports have described transient HBV infection of the Asian tree
shrew, Tupaia belangeri, in vivo (17, 20).
Furthermore, successful infection of tupaias with human herpes simplex
virus and hepatitis C virus has been described (2, 19).
Tupaias are squirrel-like animals that are closely related to primates and are endemic to subtropical areas of southeast Asia
(12). The animals are easily bred in captivity. In
addition, cultures of primary tupaia hepatocytes (PTH) can be prepared
using well-established liver perfusion protocols.
We previously described HBV infection of PTH (17);
infection efficiency was too low, however, to allow a detailed analysis of viral replicative intermediates. Here, we report that human serum
inhibits binding of HBV virions to PTH, thus limiting the maximum
multiplicity of infection. Purification of viral particles by gradient
centrifugation strongly enhances HBV binding to PTH and increases the
efficiency of infection. We further show that PTH are also susceptible
to infection with the recently discovered woolly monkey hepatitis B
virus (WMHBV) (8) and that WMHBV replicates at
higher levels in PTH than HBV.
 |
MATERIALS AND METHODS |
Animals and preparation of primary hepatocytes.
Asian tree shrews (T. belangeri) were originally obtained
from the German Primate Center in Göttingen, Germany. The animals were maintained in the animal facility of the University of Freiburg. Details of breeding conditions are available on request. Primary hepatocytes were prepared by two-step collagenase perfusion as described previously (17) with the following
modifications: the liver was perfused for 5 min via the portal vein
with Hanks solution containing 5 mM EGTA, followed by perfusion for 10 min with Hanks solution containing 5 mM CaCl2 and 0.5 mg of collagenase (HepPlus; Serva, Heidelberg, Germany)/ml. The flow
rate was 20 ml per min. The cells were seeded onto collagen-coated
six-well plates (1 million viable cells per 9.5 cm2) and kept in Hepato-STIM Hepatocyte Defined
Medium (Becton Dickinson, Bedford, Mass.). Hepato-STIM is a serum-free,
fully defined medium that was optimized for maintaining primary
hepatocytes for up to 3 weeks without loss of cellular function.
Primary rat hepatocytes were prepared and cultivated by the identical
procedure described for tupaia hepatocytes.
In vitro infection of PTH.
HBV infection was performed 1 day
after PTH preparation. After the medium was changed, the HBV inoculum
was added. HBV-positive serum was obtained from an asymptomatic chronic
HBeAg-positive individual. The viral titer was about
109 virus genome equivalents (VGE) per ml, as
estimated by comparing the Southern blot hybridization signal of
purified serum DNA with known amounts of cloned HBV DNA. Woolly monkey
serum was obtained from a colony kept in a European zoo, in which
several animals were recently found to be HBsAg positive. The viral
sequence is closely related to that reported by Lanford et al.
(8) (V. Weich, A. Wahl-Feuerstein, and M. Nassal,
unpublished data). The WMHBV titer was about 108
VGE per ml. The WHV DNA-positive woodchuck serum used in control experiments was kindly provided by Mengij Lu (University of Essen, Essen, Germany). It contained about 108 WHV VGE
per ml. Serum aliquots were stored at
20°C for up to 9 months. To
assess viral binding, the cells were incubated for 6 h at 37°C,
washed four times with culture medium, and harvested. To study viral
infection, the cells were incubated overnight (about 16 h) with
the respective viral inoculum, and culture medium was changed daily
until harvesting of the cells.
Nycodenz gradient purification of HBV particles.
In all
experiments described here, the iodinated bencoic acid derivate
Nycodenz (batch 10032780; Nycomed Pharma AS, Oslo, Norway) was
dissolved in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM
phosphate [pH 7.4]). HBV DNA-positive serum (200 µl) was loaded
onto a preformed Nycodenz gradient ranging from 8 to 50% in 11- by
34-mm polycarbonate centrifuge tubes (Beckman Instruments, Palo Alto,
Calif.). Samples were centrifuged in a TLS55 swing-out rotor (Beckman
Instruments) for 40 min at 200,000 × g at 20°C.
Subsequently, 155-µl aliquots were removed from the top of the
gradient and added to the hepatocyte culture (fraction 1, top of the
gradient; fraction 8, bottom of the gradient). More recently we found
that occasionally a precipitate entrapping most HBV virions forms in
the gradient, resulting in greatly reduced infectivity. This effect can
be avoided by dissolving Nycodenz in Hepato-STIM Hepatocyte Defined
Medium (Becton Dickinson).
Protein analysis.
Samples from the Nycodenz gradient were
mixed with Laemmli loading buffer and separated according to the
Laemmli sodium dodecyl sulfate-polyacrylamide gel electrophoresis
system on a 13% polyacrylamide gel. The proteins were either stained
with Coomassie blue or transferred onto a polyvinyldifluoride membrane
(Schleicher & Schuell, Keene, N.H.) and probed with a pre-S2/S antigen
(Ag)-specific polyclonal mouse serum generated by DNA-based
immunization (kindly provided by Michael Geissler, University Hospital
of Freiburg, Freiburg, Germany). Bound anti-HBs was visualized by
chemiluminescence using the ECLPlus system (Amersham Pharmacia Biotech,
Buckinghamshire, England).
Analysis of viral DNA.
After the culture medium was removed,
cells were lysed with 400 µl of ATL buffer (QIAamp DNA Mini Kit;
Qiagen, Hilden, Germany). The lysate was transferred to an Eppendorf
tube and digested with proteinase K (final concentration, 0.1 mg/ml)
for 1 h at 56°C. Subsequently, RNase A (final concentration,
0.02 mg/ml) was added, and DNA was purified by absorption onto silica
columns according to the protocol of the manufacturer (Qiagen). DNA was
eluted, concentrated by ethanol precipitation, and separated on a 1.3% agarose gel that did not contain ethidium bromide. Circular plasmid DNA
(0.5-kbp EcoRI/BamHI fragment of HBV in 2.7 kbp
of pUC19 vector) was used as a size marker for covalently closed
circular DNA (cccDNA). DNA purified from HBV-positive serum
served as a marker for relaxed circular viral DNA. Heat-denatured DNA
(5 min, 95°C) from HBV DNA-positive serum was used to identify the
position of single-stranded DNA (ssDNA). After electrophoresis, the gel
was soaked for 10 min in 0.25 M HCl and for 20 min in 0.5 M NaOH-1.5 M
NaCl. Nucleic acids were blotted by capillary transfer with 0.5 M
NaOH-1.5 M NaCl onto nylon membranes (Amersham Pharmacia Biotech) and
visualized by hybridization with a 32P-labeled
probe containing the complete HBV genome. This HBV probe was used to
detect all mammalian hepadnaviruses analyzed in this study. The
stringency of the final washes was 0.1% sodium dodecyl sulfate-40 mM
NaCl-4 mM sodium citrate at 60°C. Dot blot analysis was performed by
spotting 3-µl aliquots of Nycodenz gradient fractions or serum
samples onto nylon membranes. The membrane was soaked in 0.5 M
NaOH-1.5 M NaCl and 0.5 M Tris-HCl (pH 7.5)-1.5 M NaCl for 10 min
each before hybridization, as described above.
Analysis of viral RNA.
For RNA preparation, cells were lysed
with 350 µl of RLT buffer (RNeasy Mini kit; Qiagen). RNA was purified
by adsorption onto silica columns as recommended by the supplier.
Samples were treated with DNase to eliminate viral DNA. Successful
DNase digestion was verified by PCR amplification of a small aliquot of
purified RNA. The RNA was separated on morpholinopropanesulfonic
acid-buffered 1% agarose gels containing 1.2% formaldehyde. The gel
was soaked in 50 mM NaOH-1.5 M NaCl for 10 min and in 1.5 M NaCl-0.5
M Tris-HCl (pH 7.5) for 20 min. RNA was blotted onto nylon membranes by
capillary transfer with 1.5 M NaCl-150 mM sodium citrate. The position
of the rRNA was identified by staining the blotting membrane with methylene blue. HBV RNA was visualized by hybridization with the 32P-labeled HBV DNA probe, as described above.
 |
RESULTS |
Human serum competes with HBV virions for binding to
PTH.
In the previously published study of infection of PTH with
HBV, virus entry was demonstrated by the detection of newly synthesized HBV RNA in cells and secreted viral antigens in the culture medium (17). A detailed analysis of viral replicative
intermediates, however, was precluded by the low efficiency of
infection. Our main intention, therefore, was to improve the in vitro
infection protocol. First, the optimal amount of infectious serum that
should be added to a given number of PTH was determined in a virus
binding assay. PTH were incubated in 1 ml of culture medium
supplemented with increasing amounts of HBV-positive serum for 6 h
at 37°C. After being extensively washed with culture medium, the
cells were harvested and virus attachment was assessed by Southern blot analysis.
A typical experiment is shown in Fig. 1.
At low doses of serum (2 and 10 µl per ml of culture medium), the
amount of particles bound increased with increasing volume of added HBV
serum. Surprisingly, however, a higher amount of serum (50 and 200 µl
per ml of culture medium) did not result in an increase of
cell-associated viral DNA but rather reduced the number of HBV
particles attached to the cells. This effect was possibly due to an
inhibitory factor present in the serum sample used. In particular,
empty HBsAg particles might compete for HBV binding to the cells. To
address this point, 10 µl of HBV DNA-positive serum was mixed with
200 µl of anti-HBsAg-negative, HBsAg-negative normal human
serum. Virus attachment to PTH was assessed as described above.
As shown in Fig. 1, lane 6, attachment to PTH was dramatically reduced
in this experimental setting. The same effect was observed with serum
samples obtained from seven other healthy and nonvaccinated
individuals (data not shown). These results suggest that human serum
contains one or more components that compete with HBV for cellular
binding sites on PTH and that empty viral particles do not account for
the observed effects.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 1.
HBV binding to PTH. Cells were incubated for 6 h
with increasing volumes of HBV DNA-positive serum (lanes 2 to 5) or a
mixture of HBV-positive serum (10 µl) and HBV-negative human serum
(200 µl) (lane 6). HBV binding was assessed by Southern blot
analysis. Numbers on top of the figure indicate the volume of the
respective serum samples. M, 3.2-kbp linear HBV DNA; n.i., noninfected
control; RC, relaxed circular viral DNA; p.i., postincubation.
|
|
Purification of viral particles enhances binding to PTH.
Based
on the above results, it was conceivable that purification of HBV
virions from human serum might enhance binding to PTH and increase the
maximum multiplicity of infection that can be achieved in this system.
To test this hypothesis, HBV DNA-positive serum was subjected to
gradient centrifugation, and gradient fractions were analyzed by the
virus binding assay. The iodinated bencoic acid derivate Nycodenz was
chosen as a gradient medium because it is not toxic to cells in culture
and is well suited for virus purification (4). As shown in
Fig. 2A, the bulk of serum proteins floated on top of the gradient, while HBV virions readily sedimented into the gradient under our experimental conditions. Compared with
nonfractionated infectious serum, binding of gradient-purified HBV
virions to PTH was greatly enhanced (Fig. 2B). This was not due to a
nonspecific biophysical property of Nycodenz, since mixing Nycodenz
with the inoculum without sedimentation did not enhance binding (data
not shown). These results suggest that serum components which interfere
with HBV binding to PTH can be removed by gradient centrifugation.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of virus purification on viral attachment to PTH.
(A) Purification of HBV particles by Nycodenz gradient centrifugation.
(Top) Coomassie blue staining of fractionated serum proteins. (Middle)
Detection of HBsAg by Western blot analysis. (Bottom) Dot blot analysis
of viral DNA. Fractions 6, 7, and 8 contain purified virions. (B)
Binding assay with purified (right) versus nonpurified (left) viral
particles. Viral DNA was detected by Southern blot analysis. For
nomenclature, see the legend to Fig. 1.
|
|
Gradient purification of viral particles enhances the efficiency of
infection.
Next, we asked whether enhanced binding of purified HBV
virions to PTH results in enhanced infectivity. Cells were incubated overnight either with gradient-purified viral particles or with nonfractionated HBV-positive serum, followed by 6 days in culture. Cells were harvested and analyzed for viral replicative intermediates by Southern blotting. Figure 3A shows
that cccDNA, a hallmark of hepadnavirus infection (15), is
clearly visible in cells infected with purified HBV virions, while it
is hardly detectable in cells incubated with nonfractionated HBV
DNA-positive serum. DNA digestion with the restriction enzyme
NcoI generated a linear 3.2-kbp fragment, confirming the
circular nature of the respective DNA species (Fig. 3B, compare lanes 2 and 3). In a control experiment, primary rat hepatocytes were incubated
with gradient-purified HBV virions and assayed for cccDNA formation.
Figure 3B, lane 1, shows that HBV virions bound to rat hepatocytes but
no virus entry occurred, based on the lack of cccDNA formation. Thus,
purification of HBV virions by Nycodenz gradient centrifugation does
not mediate nonspecific viral uptake.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
Infection studies with purified HBV. (A) Infectivity of
purified and nonpurified virus. Viral DNA was detected by Southern blot
analysis on day 6 postinfection. Note that cccDNA is clearly
detectable only in PTH inoculated with purified virus. (B) Inoculation
of primary rat hepatocytes (lane 1) with gradient-purified HBV compared
to PTH (lane 2). Note that cccDNA is formed in PTH but not in primary
rat hepatocytes. The circular nature of the fast-migrating HBV DNA
species was confirmed by digesting the DNA with NcoI,
which cuts the HBV genome once (lane 3). (C) Time course of HBV
infection in PTH. Cells were incubated with purified HBV virions and
harvested on days 1, 7, and 16 postinfection as indicated at the top of
the figure. Viral replicative intermediates were analyzed by Southern
blot analysis. Note that cccDNA was detectable on day 7, and ssDNA was
detectable on day 16 post infection. Se, purified HBV DNA from serum;
den., denatured serum DNA; Pl, 3.2-kbp circular plasmid DNA; M, 3.2-kbp
linear HBV DNA; RC, relaxed circular viral DNA; DL, double-stranded
linear DNA.
|
|
We then performed a time course experiment with longer culture times.
As illustrated in Fig.
3C, cccDNA but not ssDNA is detectable
by
Southern blot analysis at day 7 postincubation. At day 16,
an
additional fast-migrating DNA species is visible which comigrates
with
denaturated serum HBV DNA and thus most likely represents
newly
synthesized ssDNA. The total amount of viral DNA only slightly
increased from day 7 to day 16 (Fig.
3C, compare lanes 6 and 7),
indicating that the rate of HBV replication is low in
PTH.
PTH are permissive to WMHBV infection.
WMHBV is a recently
discovered hepadnavirus that has been isolated from woolly monkeys in
captivity (8). We tested whether PTH are susceptible to
WMHBV infection. Serum from an infected woolly monkey was processed by
gradient centrifugation. PTH were incubated with gradient fractions as
described above. In a control experiment, PTH were incubated with
purified woodchuck hepatitis virus (WHV) (1, 14). Cells
were harvested at the times indicated and assayed for viral replication
by Southern blotting. While both viruses bound to PTH, cccDNA and ssDNA
formation was only observed in cells inoculated with WMHBV. Thus, PTH
are permissive to WMHBV infection (Fig.
4A) but not to WHV infection (Fig. 4B). In contrast to HBV (Fig. 3C), WMHBV ssDNA was detectable as early as 7 days postinfection, and the total amount of replicative intermediates clearly increased by day 13 postinfection, suggesting that WMHBV replicates more efficiently in PTH than does HBV.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Infection of PTH with WMHBV and WHV. (A) WMHBV-positive
serum was processed by gradient centrifugation as described for HBV.
Cells were harvested on days 1, 7, and 13 postinfection. Viral DNA was
analyzed by Southern blotting. Note that cccDNA and ssDNA are generated
in WMHBV-infected cells. (B) Control infection with WHV. PTH were
incubated with gradient-purified WHV and harvested on day 6 postinfection. Note that WHV relaxed circular DNA but no cccDNA is
visible on the Southern blot. For abbreviations, see the legend to Fig.
3.
|
|
To address this issue, the replication rates of WMHBV and HBV in PTH
were compared directly. Cells were incubated with purified
virions and
harvested at day 6 postinfection (Fig.
5A). Even though
the original WMHBV serum
contained fewer viral genome equivalents
than HBV serum, WMHBV
replicated to substantially higher levels
than HBV. In particular,
WMHBV but not HBV produced significant
amounts of ssDNA at this time
point. As one of several explanations
to account for this observation,
HBV and WMHBV might produce different
RNA levels in PTH. To test
this possibility, HBV- and WMHBV-infected
PTH were harvested at day 5 postinfection and analyzed for viral
RNA synthesis by Northern
blotting. Figure
5B illustrates that
both viruses produced abundant
amounts of pre-S/S mRNA (sgRNA),
while only low levels of
pregenomic RNA (pgRNA) were detected.
Notably, however, the ratio of
pgRNA to sgRNA was slightly higher
for WMHBV than for HBV in this
experiment.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 5.
Viral replication and transcription in HBV- and
WMHBV-infected PTH. (A) Southern blot analysis of infected PTH on day 6 postinfection (top); dot blot analysis of HBV and WMHBV serum (2 µl
each; bottom). Note that only WMHBV produced ssDNA at this time point.
For abbreviations, see the legend to Fig. 3. (B) Northern blot analysis
of infected PTH. Lysates from cells infected with fractions 6 to 8 were
pooled. pgRNA, pregenomic viral RNA. sgRNA, subgenomic viral RNA coding
for surface proteins.
|
|
 |
DISCUSSION |
We have previously reported that primary hepatocytes from
T. belangeri can be infected with HBV (17).
However, the practical use of this system was limited by the low
efficiency of infection. Here, we show that human serum interferes with
viral attachment, thereby greatly reducing viral infection. On the
other hand, purification of virions by gradient centrifugation strongly
enhances both HBV binding and infection. Thus, newly synthesized cccDNA
and ssDNA and viral RNA were unambiguously detectable by Southern and
Northern blot analysis, respectively. Infection of PTH with
Nycodenz gradient-purified HBV particles represents an authentic
biological process, because the viral host tropism was preserved in
cell culture and Nycodenz itself does not affect binding of HBV to PTH.
This is in contrast to polyethylene glycol-based protocols (6,
17), because polyethylene glycol may induce nonphysiological
membrane fusion.
The biochemical nature of the inhibitory serum component is unclear at
present. Preliminary results indicate that the inhibitory factor cannot
be removed by dialysis and that albumin and immunoglobulins, which are
the most abundant serum proteins, do not account for the inhibitory
effect (J. Köck and F. von Weizsäcker, unpublished data).
Interestingly, attachment of duck hepatitis B virus to primary duck
hepatocytes is not inhibited by duck serum (J. Köck and F. von
Weizsäcker, unpublished). This may explain in part the high
efficiency of duck hepatitis B virus infection in vitro (16).
Compared to human hepatocytes, PTH have the principal advantage of
being readily available from in-house-bred animals. PTH, therefore,
allow the highly reproducible infection with HBV under the experimental
conditions described, while the suitability of primary hepatocytes
prepared from human liver for infection experiments is very variable
(5).
PTH were also infected by WMHBV but not by WHV. This finding
substantiates PTH as a useful in vitro model system for studying hepadnavirus infection and rules out the possibility that viral uptake
in PTH is promiscuous. The permissiveness of PTH to primate but not
rodent hepadnaviruses is in line with the fact that tupaias are
phylogenetically closely related to primates but not to rodents (12).
It is important to note that the replication rate of HBV in PTH is low.
Newly synthesized HBV ssDNA was not detected until about 2 weeks
postinfection. It seems unlikely that the low replication rate of HBV
in PTH is due to inadequate cell preparation or culture conditions,
since WMHBV ssDNA was visible as early as 6 days postinfection (Fig.
5A). The precise viral and/or cellular factors determining the
replication rate of HBV and WMHBV in PTH remain to be further elucidated. Initial experiments comparing HBV and WMHBV RNA synthesis in PTH revealed an overall low abundance of pgRNA, in HBV- as well as
WMHBV-infected cells. The ratio of pgRNA to sgRNA, however, was
slightly higher in WMHBV- than in HBV-infected PTH. Since pgRNA is
pivotal for replication and capsid formation, subtle changes in pgRNA
production might translate into substantial effects on viral
replication rates. Compatible with this notion, there are significant
differences in the core promoter regions of WMHBV and HBV. We are
currently preparing a replication-competent WMHBV construct that would
allow us to directly address this question in transfected cells.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the Deutsche
Forschungs-gemeinschaft (We 1365/2-2), the Bundesministerium für
Bildung und Forschung (01Kl9951), and the Zentrum für Klinische
Forschung I (3000 0447 01 B2).
We thank H. Schaller for providing cloned HBV DNA, M. Lu for providing
WHV serum, and M. Geissler for providing mouse anti-pre-S2/S antibodies.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine II, University of Freiburg, Hugstetter Strasse 55, D-79106
Freiburg, Germany. Phone: 49-761-2703401. Fax: 49-761-2703610. E-mail:
weiz{at}ukl.uni-freiburg.de.
 |
REFERENCES |
| 1.
|
Aldrich, C. E.,
L. Coates,
T. T. Wu,
J. Newbold,
B. C. Tennant,
J. Summers,
C. Seeger, and W. S. Mason.
1989.
In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus.
Virology
172:247-252[CrossRef][Medline].
|
| 2.
|
Darai, G.,
A. Schwaiger,
D. Komitowski, and K. Munk.
1978.
Experimental infection of Tupaia belangeri (tree shrews) with herpes simplex virus types 1 and 2.
J. Infect. Dis.
137:221-226[Medline].
|
| 3.
|
Dienstag, J. L.,
E. R. Schiff,
T. L. Wright,
R. P. Perrillo,
H. W. Hann,
Z. Goodman,
L. Crowther,
L. D. Condreay,
M. Woessner,
M. Rubin, and N. A. Brown.
1999.
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N. Engl. J. Med.
341:1256-1263[Abstract/Free Full Text].
|
| 4.
|
Fowler, E.,
N. Raab-Traub, and S. Hester.
1985.
Purification of biologically active Epstein-Barr virus by affinity chromatography and nonionic density gradient centrifugation.
J. Virol. Methods
11:59-74[CrossRef][Medline].
|
| 5.
|
Galle, P. R.,
J. Hagelstein,
B. Kommerell,
M. Volkmann,
P. Schranz, and H. Zentgraf.
1994.
In vitro experimental infection of primary human hepatocytes with hepatitis B virus.
Gastroenterology
106:664-673[Medline].
|
| 6.
|
Gripon, P.,
C. Diot, and C. Guguen-Guillouzo.
1993.
Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration.
Virology
192:534-540[CrossRef][Medline].
|
| 7.
|
Hoofnagle, J., and A. M. DiBisceglie.
1997.
The treatment of chronic viral hepatitis.
N. Engl. J. Med.
336:347-356[Free Full Text].
|
| 8.
|
Lanford, R. E.,
D. Chavez,
K. M. Brasky,
R. B. Burns III, and R. Rico-Hesse.
1998.
Isolation of a hepadnavirus from the woolly monkey, a New World primate.
Proc. Natl. Acad. Sci. USA
95:5757-5761[Abstract/Free Full Text].
|
| 9.
|
Lee, W. M.
1997.
Hepatitis B virus infection.
N. Engl. J. Med.
337:1733-1745[Free Full Text].
|
| 10.
|
Lemon, S. M., and D. L. Thomas.
1997.
Vaccines to prevent viral hepatitis.
N. Engl. J. Med.
336:196-204[Free Full Text].
|
| 11.
|
Nassal, M., and H. Schaller.
1993.
Hepatitis B virus replication.
Trends Microbiol.
1:221-228[CrossRef][Medline].
|
| 12.
|
Novacek, M. J.
1992.
Mammalian phylogeny: shaking the tree.
Nature
356:121-125.
|
| 13.
|
Seeger, C., and W. S. Mason.
2000.
Hepatitis B virus biology.
Microbiol. Mol. Biol. Rev.
64:51-68[Abstract/Free Full Text].
|
| 14.
|
Summers, J.,
J. M. Smolec, and R. Snyder.
1978.
A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks.
Proc. Natl. Acad. Sci. USA
75:4533-4537[Abstract/Free Full Text].
|
| 15.
|
Tuttleman, J. S.,
C. Pourcel, and J. Summers.
1986.
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells.
Cell
47:451-460[CrossRef][Medline].
|
| 16.
|
Tuttleman, J. S.,
J. C. Pugh, and J. W. Summers.
1986.
In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus.
J. Virol.
58:17-25[Abstract/Free Full Text].
|
| 17.
|
Walter, E.,
R. Keist,
B. Niederöst,
I. Pult, and H. E. Blum.
1996.
Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo.
Hepatology
24:1-5[CrossRef][Medline].
|
| 18.
|
Wright, T. L., and J. Y. Lau.
1993.
Clinical aspects of hepatitis B virus infection.
Lancet
342:1340-1344[CrossRef][Medline].
|
| 19.
|
Xie, Z. C.,
J. I. Riezu-Boj,
J. J. Lasarte,
J. Guillen,
J. H. Su,
M. P. Civeira, and J. Prieto.
1998.
Transmission of hepatitis C virus infection to tree shrews.
Virology
244:513-520[CrossRef][Medline].
|
| 20.
|
Yan, R. Q.,
J. J. Su,
D. R. Huang,
Y. C. Gan,
C. Yang, and G. H. Huang.
1996.
Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus.
J. Cancer Res. Clin. Oncol.
122:283-288[CrossRef][Medline].
|
Journal of Virology, June 2001, p. 5084-5089, Vol. 75, No. 11
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5084-5089.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hantz, O., Parent, R., Durantel, D., Gripon, P., Guguen-Guillouzo, C., Zoulim, F.
(2009). Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J. Gen. Virol.
90: 127-135
[Abstract]
[Full Text]
-
Gudima, S., He, Y., Chai, N., Bruss, V., Urban, S., Mason, W., Taylor, J.
(2008). Primary Human Hepatocytes Are Susceptible to Infection by Hepatitis Delta Virus Assembled with Envelope Proteins of Woodchuck Hepatitis Virus. J. Virol.
82: 7276-7283
[Abstract]
[Full Text]
-
Zhang, P., Yu, M.-y. W., Venable, R., Alter, H. J., Shih, J. W.-K.
(2006). Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc. Natl. Acad. Sci. USA
103: 9214-9219
[Abstract]
[Full Text]
-
Rabe, B., Glebe, D., Kann, M.
(2006). Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events.. J. Virol.
80: 5465-5473
[Abstract]
[Full Text]
-
Barrera, A., Guerra, B., Notvall, L., Lanford, R. E.
(2005). Mapping of the Hepatitis B Virus Pre-S1 Domain Involved in Receptor Recognition. J. Virol.
79: 9786-9798
[Abstract]
[Full Text]
-
Barth, H., Cerino, R., Arcuri, M., Hoffmann, M., Schurmann, P., Adah, M. I., Gissler, B., Zhao, X., Ghisetti, V., Lavezzo, B., Blum, H. E., von Weizsacker, F., Vitelli, A., Scarselli, E., Baumert, T. F.
(2005). Scavenger Receptor Class B Type I and Hepatitis C Virus Infection of Primary Tupaia Hepatocytes. J. Virol.
79: 5774-5785
[Abstract]
[Full Text]
-
Glebe, D., Aliakbari, M., Krass, P., Knoop, E. V., Valerius, K. P., Gerlich, W. H.
(2003). Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus. J. Virol.
77: 9511-9521
[Abstract]
[Full Text]
-
Kock, J., Kann, M., Putz, G., Blum, H. E., von Weizsacker, F.
(2003). Central Role of a Serine Phosphorylation Site within Duck Hepatitis B Virus Core Protein for Capsid Trafficking and Genome Release. J. Biol. Chem.
278: 28123-28129
[Abstract]
[Full Text]
-
Prassolov, A., Hohenberg, H., Kalinina, T., Schneider, C., Cova, L., Krone, O., Frolich, K., Will, H., Sirma, H.
(2003). New Hepatitis B Virus of Cranes That Has an Unexpected Broad Host Range. J. Virol.
77: 1964-1976
[Abstract]
[Full Text]